Novogen (KZIA) Stock Price, News & Analysis

Company Overview

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

Key Stats

• Today's Range: $10.59 to $11.50
• 50-Day Range: $7.16 to $14.44
• 52-Week Range: $4.86 to $17.40
• Volume: 189,801 shs
• Average Volume: 197,319 shs
• Market Capitalization: $18.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

Novogen Stock Analysis - MarketRank™

Novogen scored higher than 38% of companies evaluated by MarketBeat, and ranked 664th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Novogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Novogen has a consensus price target of $21.00, representing about 91.1% upside from its current price of $10.99.

Amount of Analyst Coverage

Novogen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Novogen are expected to remain at ($0.01) per share in the coming year.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

22.17% of the float of Novogen has been sold short.

Short Interest Ratio / Days to Cover

Novogen has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novogen has recently decreased by 11.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novogen does not currently pay a dividend.

Dividend Growth

Novogen does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Novogen this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Novogen is held by insiders.

Percentage Held by Institutions

30.89% of the stock of Novogen is held by institutions.

Company Calendar

• Last Earnings: 2/14/2026
• Today: 6/07/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• Previous Symbol: ASX:KZA
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Novogen: $21.00
• High Price Target: $25.00
• Low Price Target: $18.00
• Potential Upside/Downside: +91.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.87
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 604.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.34) per share
• Price / Book: -2.06

Miscellaneous

• Outstanding Shares: 1,650,000
• Free Float: 1,636,000
• Market Cap: $18.13 million
• Optionable: No Data
• Beta: 2.17